These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 34959980)

  • 81. Reversal of Hepatic Dysfunction After Exceptional Responses to Lenvatinib.
    Muquith M; Espinoza M; Hsiehchen D
    J Gastrointest Cancer; 2023 Sep; 54(3):982-985. PubMed ID: 35939228
    [No Abstract]   [Full Text] [Related]  

  • 82. Influence of skeletal muscle volume loss during lenvatinib treatment on prognosis in unresectable hepatocellular carcinoma: a multicenter study in Tohoku, Japan.
    Fujita M; Abe K; Kuroda H; Oikawa T; Ninomiya M; Masamune A; Okumoto K; Katsumi T; Sato W; Iijima K; Endo T; Fukuda S; Tanabe N; Numao H; Takikawa Y; Ueno Y; Ohira H
    Sci Rep; 2022 Apr; 12(1):6479. PubMed ID: 35444161
    [TBL] [Abstract][Full Text] [Related]  

  • 83. [Preclinical study for antitumor mechanism of lenvatinib and clinical studies for hepatocellular carcinoma].
    Watanabe T; Koyama N
    Nihon Yakurigaku Zasshi; 2019; 153(5):242-248. PubMed ID: 31092758
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Adverse impact of low skeletal muscle index on the prognosis of hepatocellular carcinoma after hepatic resection.
    Yabusaki N; Fujii T; Yamada S; Suzuki K; Sugimoto H; Kanda M; Nakayama G; Koike M; Fujiwara M; Kodera Y
    Int J Surg; 2016 Jun; 30():136-42. PubMed ID: 27154615
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Skeletal muscle depletion predicts the prognosis of patients with hepatocellular carcinoma treated with sorafenib.
    Imai K; Takai K; Hanai T; Ideta T; Miyazaki T; Kochi T; Suetsugu A; Shiraki M; Shimizu M
    Int J Mol Sci; 2015 Apr; 16(5):9612-24. PubMed ID: 25927582
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Liver Function and Bleeding Complications Associated with Lenvatinib.
    Ishihara K
    J Gastrointestin Liver Dis; 2021 May; 30(2):185-187. PubMed ID: 33951114
    [No Abstract]   [Full Text] [Related]  

  • 87. Effect of levocarnitine supplementation on myocardial strain in children with acute kidney injury receiving continuous kidney replacement therapy: a pilot study.
    Sgambat K; Clauss S; Moudgil A
    Pediatr Nephrol; 2021 Jun; 36(6):1607-1616. PubMed ID: 33389092
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Association between Levocarnitine Treatment and the Change in Knee Extensor Strength in Patients Undergoing Hemodialysis: A Post-Hoc Analysis of the Osaka Dialysis Complication Study (ODCS).
    Matsufuji S; Shoji T; Lee S; Yamaguchi M; Nishimura M; Tsujimoto Y; Nakatani S; Morioka T; Mori K; Emoto M
    Nutrients; 2022 Jan; 14(2):. PubMed ID: 35057527
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Comparison of standard-dose and half‑dose sorafenib therapy on clinical outcome in patients with unresectable hepatocellular carcinoma in field practice: A propensity score matching analysis.
    Nishikawa H; Osaki Y; Endo M; Takeda H; Tsuchiya K; Joko K; Ogawa C; Taniguchi H; Orito E; Uchida Y; Izumi N;
    Int J Oncol; 2014 Dec; 45(6):2295-302. PubMed ID: 25230744
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Clinical Outcomes of 2nd- and 3rd-Line Regorafenib for Advanced Hepatocellular Carcinoma.
    Naruto K; Kawaoka T; Amioka K; Ogawa Y; Chihiro K; Yoshikawa Y; Ando Y; Suehiro Y; Kosaka Y; Uchikawa S; Kodama K; Morio K; Fujino H; Murakami E; Nakahara T; Yamauchi M; Tsuge M; Hiramatsu A; Fukuhara T; Takaki S; Mori N; Tsuji K; Nonaka M; Hyogo H; Aisaka Y; Masaki K; Honda Y; Kohno H; Kohno H; Moriya T; Naeshiro N; Azakami T; Imamura M; Chayama K; Aikata H
    Oncology; 2021; 99(8):491-498. PubMed ID: 34000725
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Supplementation with branched-chain amino acids ameliorates hypoalbuminemia, prevents sarcopenia, and reduces fat accumulation in the skeletal muscles of patients with liver cirrhosis.
    Kitajima Y; Takahashi H; Akiyama T; Murayama K; Iwane S; Kuwashiro T; Tanaka K; Kawazoe S; Ono N; Eguchi T; Anzai K; Eguchi Y
    J Gastroenterol; 2018 Mar; 53(3):427-437. PubMed ID: 28741271
    [TBL] [Abstract][Full Text] [Related]  

  • 92. [Value of lenvatinib for the treatment of advanced hepatocellular carcinoma].
    Yuan B; Wang Y; Zhang JL; Yan JY; Yuan K; Wang XQ; Fu JX; Duan F; Wang MQ
    Zhonghua Yi Xue Za Zhi; 2020 Mar; 100(11):833-836. PubMed ID: 32234154
    [No Abstract]   [Full Text] [Related]  

  • 93. Neutrophil-to-lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib.
    Tada T; Kumada T; Hiraoka A; Michitaka K; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Yasuda S; Toyoda H; Fukunishi S; Ohama H; Kawata K; Nakamura S; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Arai T; Imai M; Joko K; Koizumi Y; Hiasa Y
    Liver Int; 2020 Apr; 40(4):968-976. PubMed ID: 32064740
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma.
    Rapposelli IG; Shimose S; Kumada T; Okamura S; Hiraoka A; Di Costanzo GG; Marra F; Tamburini E; Forgione A; Foschi FG; Silletta M; Lonardi S; Masi G; Scartozzi M; Nakano M; Shibata H; Kawata K; Pellino A; Vivaldi C; Lai E; Takata A; Tajiri K; Toyoda H; Tortora R; Campani C; Viola MG; Piscaglia F; Conti F; Fulgenzi CAM; Frassineti GL; Rizzato MD; Salani F; Astara G; Torimura T; Atsukawa M; Tada T; Burgio V; Rimini M; Cascinu S; Casadei-Gardini A
    ESMO Open; 2021 Aug; 6(4):100190. PubMed ID: 34144271
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Cohort Study.
    Shimose S; Kawaguchi T; Iwamoto H; Tanaka M; Miyazaki K; Ono M; Niizeki T; Shirono T; Okamura S; Nakano M; Suga H; Yamaguchi T; Yokokura Y; Noguchi K; Koga H; Torimura T
    Nutrients; 2020 Apr; 12(4):. PubMed ID: 32295043
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Trends in Hepatic Functional Reserve of Patients with Hepatocellular Carcinoma Treated with Tyrosine Kinase Inhibitors.
    Uchikawa S; Kawaoka T; Ando Y; Yamaoka K; Kosaka Y; Suehiro Y; Fujii Y; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Takahashi S; Chayama K; Aikata H
    Oncology; 2020; 98(10):727-733. PubMed ID: 32712613
    [TBL] [Abstract][Full Text] [Related]  

  • 97. C-reactive protein can predict dose intensity, time to treatment failure and overall survival in HCC treated with lenvatinib.
    Hayashi T; Shibata M; Oe S; Miyagawa K; Honma Y; Harada M
    PLoS One; 2020; 15(12):e0244370. PubMed ID: 33351844
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Lenvatinib-Induced Tumor-Related Hemorrhage in Patients With Unresectable Hepatocellular Carcinoma.
    Kotani K; Uchida-Kobayashi S; Yoshida K; Kawamura E; Fujii H; Hagihara A; Enomoto M; Tamori A; Kawada N
    Am J Gastroenterol; 2021 Apr; 116(4):631. PubMed ID: 33982923
    [No Abstract]   [Full Text] [Related]  

  • 99. Targeting Hedgehog signalling in CD133-positive hepatocellular carcinoma: improving Lenvatinib therapeutic efficiency.
    Hu Q; Hu X; Zhang L; Zhao Y; Li L
    Med Oncol; 2021 Mar; 38(4):41. PubMed ID: 33730237
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Perforating dermatosis associated with multikinase inhibitors: report of two cases, including one associated with lenvatinib.
    Sato-Sano M; Cury-Martins J; Macarenco R; Domingues RB; Vasconcelos R; Sanches JA
    J Dtsch Dermatol Ges; 2018 Dec; 16(12):1486-1489. PubMed ID: 30466160
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.